Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson Sells 1,000 Shares

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 1,000 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00. Following the transaction, the vice president now directly owns 2,368 shares in the company, valued at approximately $47,360. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brent Johnson also recently made the following trade(s):

  • On Thursday, September 12th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.25, for a total transaction of $20,250.00.
  • On Wednesday, August 21st, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.62, for a total transaction of $20,620.00.
  • On Monday, August 19th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.21, for a total transaction of $21,210.00.
  • On Friday, August 16th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $20.92, for a total transaction of $41,840.00.
  • On Wednesday, August 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.10, for a total transaction of $21,100.00.
  • On Monday, August 12th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.27, for a total transaction of $21,270.00.
  • On Friday, August 9th, Brent Johnson sold 2,400 shares of Iradimed stock. The stock was sold at an average price of $21.81, for a total transaction of $52,344.00.
  • On Monday, August 5th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.94, for a total transaction of $65,820.00.
  • On Wednesday, August 7th, Brent Johnson sold 7,000 shares of Iradimed stock. The stock was sold at an average price of $21.93, for a total transaction of $153,510.00.
  • On Friday, August 2nd, Brent Johnson sold 5,000 shares of Iradimed stock. The stock was sold at an average price of $22.83, for a total transaction of $114,150.00.

NASDAQ IRMD traded down $0.14 during trading hours on Thursday, reaching $20.31. The company’s stock had a trading volume of 48,700 shares, compared to its average volume of 68,404. The company has a current ratio of 10.29, a quick ratio of 9.39 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $20.32 and a 200 day simple moving average of $22.67. Iradimed Corp has a 52 week low of $16.68 and a 52 week high of $38.78. The stock has a market cap of $234.45 million, a PE ratio of 47.23 and a beta of 1.67.

Hedge funds and other institutional investors have recently modified their holdings of the business. HM Payson & Co. bought a new position in Iradimed in the second quarter worth about $89,000. Victory Capital Management Inc. bought a new position in Iradimed in the first quarter worth about $212,000. Charles Schwab Investment Management Inc. lifted its holdings in Iradimed by 34.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 10,500 shares of the medical equipment provider’s stock worth $215,000 after acquiring an additional 2,666 shares during the last quarter. Marshall Wace LLP bought a new position in Iradimed in the first quarter worth about $241,000. Finally, Morgan Stanley lifted its holdings in Iradimed by 14.3% in the second quarter. Morgan Stanley now owns 13,118 shares of the medical equipment provider’s stock worth $268,000 after acquiring an additional 1,637 shares during the last quarter. 30.63% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on IRMD shares. ValuEngine raised shares of Iradimed from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Zacks Investment Research cut shares of Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Article: Are all No-Load Funds Equal?

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.